TriSalus Life Sciences (TLSI) Equity Average (2022 - 2025)
Historic Equity Average for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$23.1 million.
- TriSalus Life Sciences' Equity Average fell 351.03% to -$23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.1 million, marking a year-over-year decrease of 351.03%. This contributed to the annual value of -$26.5 million for FY2024, which is 7396.25% up from last year.
- As of Q3 2025, TriSalus Life Sciences' Equity Average stood at -$23.1 million, which was down 351.03% from -$26.9 million recorded in Q2 2025.
- Over the past 5 years, TriSalus Life Sciences' Equity Average peaked at -$9.3 million during Q4 2023, and registered a low of -$191.4 million during Q2 2023.
- For the 4-year period, TriSalus Life Sciences' Equity Average averaged around -$55.7 million, with its median value being -$28.2 million (2024).
- Examining YoY changes over the last 5 years, TriSalus Life Sciences' Equity Average showed a top increase of 9011.75% in 2023 and a maximum decrease of 140589.7% in 2023.
- TriSalus Life Sciences' Equity Average (Quarter) stood at -$94.0 million in 2022, then skyrocketed by 90.12% to -$9.3 million in 2023, then crashed by 149.37% to -$23.2 million in 2024, then grew by 0.39% to -$23.1 million in 2025.
- Its last three reported values are -$23.1 million in Q3 2025, -$26.9 million for Q2 2025, and -$30.1 million during Q1 2025.